ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2020

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.

Jim S Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.